REG - Genflow Biosciences - Total Voting Rights

Genflow BiosciencesAnnouncement

30/05/2025 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250530:nRSd8567Ka&default-theme=true

RNS Number : 8567K  Genflow Biosciences PLC  30 May 2025

30 May 2025

 

Genflow Biosciences plc

("Genflow" or the "Company")

 

Total Voting Rights

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company")
announces that the total issued share capital of the Company as at 30 May 2025
consists of 453,547,942 ordinary shares of £0.0003 each, none of which are
held in treasury. Therefore, the total number of voting rights in the Company
is 453,547,942.

The figure of 453,547,942 ordinary shares may be used by shareholders of the
Company as the denominator for the calculations by which they will determine
if they are required to notify their investment in, or a change in their
interest in, the share capital of the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.

 

Contacts

 Genflow Biosciences                           Harbor Access
 Dr Eric Leire, CEO                            Jonathan Paterson, Investor Relations
 +32-477-495-881                               +1 475 477 9401
                                               Jonathan.Paterson@Harbor-access.com
 Corporate Brokers
 Capital Plus Partners Ltd
 Jon Critchley, +44 0203 821 6168

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population.

 

Genflow's lead compound, GF-1002, works through the delivery of a centenarian
variant of the SIRT6 gene which has yielded promising preclinical results.
Expected to begin in 2025, Genflow's clinical trial aims to explore the
potential benefits of GF-1002 in treating MASH (Metabolic
Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver
disease for which there is no effective treatments. Please
visit www.genflowbio.com (http://www.genflowbio.com/)   and follow the
Company on LinkedIn and Twitter/X.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRWPUMGAUPAGCU